TCT 2023 Late-Breaking Science Collection
Published: 09 January 2024
-
Views:
319
-
Likes:
7
-
Views:
319
-
Likes:
7
-
Up Next -
30m 36sPart 1 | Session 2 View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up
-
8m 13sPart 2 | Session 1 5 Trials That Will Change My Practice With Dr Kendra Grubb -
14m 10sPart 2 | Session 2 5 Trials That Will Change My Practice With Dr Mirvat Alasnag -
12m 36sPart 2 | Session 3 5 Trials That Will Change My Practice With Dr Bernardo Cortese
-
7m 42sPart 3 | Session 1 5Y Outcomes From the PARTNER 3 Low-Risk Trial -
6m 43s -
8m 46sPart 3 | Session 3 Four-Year Outcomes from the EVOLUT Low Risk Trial -
11m 22s -
6m 19sPart 3 | Session 5 WATCH-TAVR: WATCHMAN for Patients with AF Undergoing TAVR -
7m 14s
Overview
Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations.
Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Highlights
Part 3
Interviews
About the episode
What's hot at TCT 2023?
In this episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the late-breaking data presented at TCT 2023.
With their dynamic analysis, these anticipated trials are placed in context, highlighting the real-world implications tied to the data releases.
Top trials covered:
00:31 - 02:12: PARTNER 3 Low-Risk: Five-Year Clinical and Echocardiographic Outcomes
02:12 - 03:25: EVOLUT Low-Risk: Four-Year Outcomes From the EVOLUT Low Risk Trial
03:25- 05:33: ALIGN-AR: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement
05:33 - 07:51: VIVA: Transcatheter versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annuli
08:14 - 10:19: AGENT IDE: Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT
10:19 - 13:10: DCB-ACS: Drug-Coated Balloon for Acute Coronary Syndromes
13:10 - 15:28:T-PASS: Less Than 1-month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy after Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome
15:28 - 17:48: WATCH TAVR: Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve
17:48 - 18:59: TRILUMINATE: Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation
18:59 - 21:06: TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients With Severe Tricuspid Regurgitation
21:06 - 23:24: PICSO-AMI-I: Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction
23:24 - 25:27: RADIANCE: Individual Patient-data Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure at 6 Months
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Comments